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Abstract
It is likely that the majority of proteins will undergo 
post-translational modification, be it enzymatic or 
non-enzymatic. These modified protein(s) regulate 
activity, localization and interaction with other cellular 
molecules thereby maintaining cellular hemostasis. 
Alcohol exposure significantly alters several of these 
post-translational modifications leading to impairments 
of many essential physiological processes. Here, we 
present new insights into novel modifications following 
ethanol exposure and their role in the initiation 
and progression of liver injury. This critical review 
condenses the proceedings of a symposium at the 
European Society for the Biomedical Research on 
Alcoholism Meeting held September 12-15, 2015, in 
Valencia, Spain.
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and ISGylation. Directed or inadvertent exposure to 
stressful factors, including chronic ethanol exposure, 
has been shown to cause aberrant post-translational 
modifications. Additionally, bioactive products of 
enzymatic or non-enzymatic lipid oxidation may also 
cause protein modifications with potential functional 
damage to protein[11] as well as impact the function of 
various metabolic pathways. This brief overview will 
focus on recent advances that have been made using 
global proteomic approaches and bioinformatics to 
better understand the impact of these altered post-
translational modifications by ethanol. 
Alcohol consumption significantly alters several 
post-translational modifications of proteins and this has 
been reviewed recently[10]. Here, we review the newly 
described and pathogenically relevant alterations that 
play important roles in the progression of ALD. First we 
discuss the undesired post-translational modifications 
that may occur via electrophilic species including 
reactive aldehydes (carbonylation), acyl groups 
(acetylation) and sugar moieties (glycosylation).
CARBONYLATION
A key contributor to the pathogenesis of ALD is 
enhanced hepatocellular oxidative stress resulting 
from the production of reactive oxygen species via 
induction of Cyp2E1 as well as xanthine and NADPH 
oxidases[12-16]. These reactive species, in turn, induce 
lipid peroxidation of unsaturated fatty acids including 
linoleic acid forming α/β unsaturated aldehydes[17,18]. 
The best characterized of these carbonyl-derivatives 
include 4-hydroxy-2-nonenal (4-HNE), 4-oxo-2-nonenal, 
malondialdehyde (MDA) and acrolein. Following their 
formation, these highly reactive lipid electrophiles 
modify DNA as well as lysine, cysteine and histidine 
residues on proteins, thereby impairing their structural 
or catalytic capabilities. Early proteomic approaches to 
identify carbonylated proteins in ALD used 2-dimensional 
electrophoresis followed by protein identification. These 
techniques were not very sensitive and only a handful 
of proteins were identified[19,20]. A commonality of all 
these proteins was the fact that all were very highly 
expressed, which permitted easier identification. 
Of interest, the majority of identified proteins were 
involved in either protein folding (heat shock proteins) 
or hepatocellular oxidative stress responses.
Recent advances in biotin hydrazide chemistry 
and in the sensitivity of mass spectrometry have 
allowed for a more in depth proteomic approach to 
identify less abundant proteins modified by reactive 
aldehydes in ALD. To date, using global proteomic 
approaches, over 2000 proteins that undergo 
carbonylation have been identified in either murine 
models or in human hepatic tissue isolated from 
patients with end-stage ALD[21-23]. Using enriched 
cellular fractions, chronic ethanol consumption led 
to an increase in carbonylation of microsomal and 
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Core tip: A majority of proteins in our body undergo 
orchestrated post-translational modifications that 
influence protein structure and function. Chronic 
ethanol administration causes aberrant post-trans-
lational modification of proteins that play a critical role 
in the pathogenesis of alcoholic-induced liver damage. 
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INTRODUCTION
Ethanol consumption leads to many adverse functional 
and structural molecular changes in multiple organs and 
accounts for 2.5 million deaths globally each year[1,2]. 
Ethanol is mainly metabolized in the liver; this organ 
is therefore most susceptible to its toxic effects[3,4]. 
Sustained alcohol misuse produces a wide spectrum 
of hepatic lesions, the most characteristic being 
steatosis, hepatitis and fibrosis/cirrhosis[5]. Steatosis, 
characterized by fat accumulation in hepatocytes, 
develops in 90% of individuals who drink more than 
16 g of alcohol per day[6]. In 30%-40% of individuals 
reporting chronic alcohol abuse, there is development 
of hepatitis which is characterized by inflammatory 
changes in the liver and ballooning degeneration of 
hepatocytes. In later stages of alcoholic liver disease 
(ALD), collagen deposition and regenerative nodules 
can result in the development of fibrosis and cirrhosis, 
respectively[2]. Better understanding of the mechanisms 
by which alcohol damages the liver may yield new 
pharmacologic strategies to blunt, halt, or reverse 
disease progression, potentially even in inveterate 
alcoholics.
Hepatic dysfunction due to chronic ethanol 
consumption is multifactorial involving dysregulation 
of multiple cellular pathways[7-9]. Significant to the 
aforementioned dysregulation is abnormal post-trans-
lational modification of proteins[10]. About 50%-90% 
of proteins in our body undergo orchestrated post-
translational modifications that could influence 
protein structure and function. These modifications 
may be enzymatic or non-enzymatic and play an 
important role in functions of proteins through the 
regulation of activity, turnover and localization and/or 
interactions to maintain cellular hemostasis. These 
modifications include phosphorylation, acetylation, 
methylation, glycosylation, ubiquitination, sumoylation 
cytosolic proteins. Comprehensive pathway analysis of 
identified proteins revealed that ethanol consumption 
impacted many different cellular pathways foremost 
of which are the fatty acid metabolic, tricarboxylic 
acid cycle and amino acid metabolism. By increasing 
carbonylation of proteins involved in these pathways, 
mechanistic links have been proposed for ethanol’
s impact on lipid accumulation as well as how acetyl 
CoA contributes to nutritional imbalances evident 
in alcoholics. These findings are further supported 
by an additional study that examined the effects of 
deletion of glutathione S-transferase A4-4 (GSTA4-4) 
which functions to remove 4-HNE reducing the effects 
of reactive aldehydes[24]. Using GSTA4-4 knockout 
mice and employing proteomics approaches, it 
was determined that carbonylation was increased 
in mitochondrial fractions especially in pathways 
regulating oxidative stress, fatty acid metabolism and 
amino acid metabolism supporting the contribution 
of GSTA4-4 in protecting mitochondria from reactive 
aldehydes (Supplementary Table 1). Concurrently, 
we have reported that carbonylation is increased 
in tissue obtained from end-stage alcoholics[23]. 
Not surprisingly, following mass spectral analysis, 
increased carbonylation of proteins regulating oxidative 
stress, metabolic and cytoskeletal processes were 
increased[24].
GLYCOSYLATION
In cells, glycosylation of proteins contributes to 
numerous cellular functions including assisting in 
proper protein folding as well as cell to cell adhesion. 
Global proteomic approaches and 2-dimensional 
electrophoresis were performed on microsomal 
fractions consisting primarily of smooth and rough 
endoplasmic reticulum, isolated from chronically 
ethanol fed mice. These studies revealed a significantly 
decrease in microsomal glycosylation following 8 wk 
of alcohol consumption. Subsequent bioinformatic 
pathway analysis revealed significant decreases in 
glycosylation of proteins regulating protein folding, 
redox homeostasis and the unfolded protein response 
among others. These results suggest that decreased 
glycosylation may contribute to the observed increased 
in ubiquitinated proteins in murine models of ALD[25].
ACETYLATION
In hepatocytes, acetylation of lysine residues results 
in regulation of many cellular functions including gene 
expression and metabolism. As it is metabolized, 
ethanol is converted to acetaldehyde by alcohol 
dehydrogenases followed by removal of the aldehyde 
group by mitochondrial aldehyde dehydrogenases 
(ALDH2) to produce acetate, which is converted to 
acetyl CoA[26]. By way of protein acyl transferases, 
acetyl CoA is then utilized in part as a substrate for 
protein acetylation. Therefore, it is not surprising 
that over the last decade, ethanol abuse has been 
determined to directly affect protein acetylation[27-30]. In 
murine models of ALD, ethanol decreases expression of 
the class Ⅲ nicotinamide adenine dinucleotide (NAD+/
NADH) dependent protein deacetylases, Sirtuin 1 
(SIRT1) and Sirtuin 5 and decreases enzymatic activity 
of Sirtuin 3[31-35]. All these changes combined decrease 
the overall cellular deacetylase activity that ultimately 
results in an increase in protein acetylation. Using 
traditional Western blotting and immunoprecipitation 
techniques chronic ethanol induces hyperacetylation of 
several key metabolic regulators, including PPARγ co-
activator 1α, sterol regulatory binding element protein 
1 (SREBP-1c) and forkhead transcription factor 1.
In recent experiments, mass spectrometry and 
proteomic approaches have been applied to identify 
proteins and pathways that are acetylated following 
chronic ethanol consumption. Using whole cell extracts 
and matrix-assisted laser desorption mass spectrometry, 
Shepard et al[30] identified 40 proteins that are 
acetylated following chronic ethanol administration. 
Pathway analysis revealed that of these 40, the majority 
was predominantly mitochondrial proteins and there 
was a significant preference for proteins regulating 
lipid metabolism as well as oxidative stress[29,30]. More 
recently using mitochondrial enriched fractions isolated 
from ethanol-fed wild-type and SIRT3 knockout mice, 
we determined that chronic ethanol impacted acetylation 
of proteins regulating lipid metabolism, oxidative stress, 
as well as mitochondrial pathways including amino acid 
biosynthesis and the electron transport chain[32]. 
SUMOYLATION
A member of the ubiquitin family, SUMO, comprised of 
four distinct proteins in humans (SUMO-1, -2, -3 and 
-4), is receiving growing interest since its discovery 
less than a decade ago[36]. SUMO-4 shows similarity to 
-2/3 but it is as yet unclear whether it is a pseudogene 
or merely restricted in its expression pattern[37]. The 
sumoylation cycle is a multistep process, involving 
maturation, activation, conjugation and deconjugation, 
and regulates the function and fate of a large number 
of proteins involved in many cellular pathways including 
transcription, intracellular transport, DNA repair, 
replication, and cell signaling[38,39]. Sumoylation, as an 
enzymatic cascade, resembles that of ubiquitination, 
including an ATP dependent step, the E1-activating 
enzyme Aos1/Uba2 (SAE1/SAE2) forms a thioester 
bond between its catalytic cysteine (Uba2 C173) and 
the C-terminal carboxy group of mature SUMO. From 
there, SUMO is transferred to the catalytic cysteine 
(C93) of the E2-conjugating enzyme (Ubc9). In the 
last step of this cascade, an isopeptide bond is formed 
between SUMO and the 3-amino group of a lysine side 
chain. Specific isopeptidases, members of the SENP 
family, ensure reversibility of this modification[40,41]. 
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catalysed remethylation of homocysteine to generate 
methionine, the metabolic precursor of SAM. A 
subsequent depletion of SAM availability limits the 
activity of SAM-dependent methyltransferases, such 
as PIMT. This inhibition of methylation reactions is 
further exacerbated by the ethanol-induced increase 
in the level of S-adenosylhomocysteine (SAH), a 
potent inhibitor of numerous SAM-dependent methyl-
transferases including PIMT[49,51-54].
Animal studies have demonstrated the benefits 
of dietary supplementation with betaine, a pro-
methylating agent, to counter some of the ethanol-
induced changes in the metabolite levels of the 
methionine metabolic pathway[49,51-54]. Rats fed a 
control or ethanol liquid diet (36% of calories) for a 
period of 4 wk with or without dietary supplementation 
with 1% betaine revealed that the ethanol-induced 
reduction of the methylation potential (i.e,. the 
lowering of the hepatocellular SAM:SAH ratio to 
approximately 43% of control level) was rectified 
in rats fed an ethanol diet supplemented with 
betaine[49,51-54]. Concomitant with the changes in 
the SAM:SAH ratio, the ethanol-induced increase of 
damage to cellular proteins as isoaspartate was also 
alleviated by betaine supplementation[49,51-54].
A proteomic approach was adopted to investigate 
the mechanism by which betaine was able to 
alleviate the ethanol-induced increase of isoaspartate 
damage. One dimensional and two dimensional 
protein separations and differential protein staining 
techniques revealed that betaine supplementation 
increased the expression of betaine homocysteine 
methyltransferase-1, methionine adenosyl trans-
ferase-1 and glycine N-methyltransferase, and these 
enzymes act to collectively increase SAM levels and 
normalise the SAM:SAH ratio[55].
To further investigate the influence of the SAM:
SAH ratio on PIMT activity and cellular isoaspartate 
damage, primary hepatocytes taken from control or 
ethanol-fed rats were cultured. Cells were incubated 
in vitro with tubercidin or adenosine, agents that 
elevate cellular SAH levels[56]. These agents produced 
an additive increase of isoaspartate damage to that 
detected from ethanol consumption, indicative of an 
additional lowering of the SAM:SAH ratio and further 
inhibition of PIMT activity. 
To identify liver protein target(s) of PIMT that 
accrue isoaspartate damage after ethanol consum-
ption, proteins from control and ethanol fed rats were 
exogenously methylated using PIMT and 3H-SAM 
methyl donor. Novel, sensitive autoradiographic 
imaging[57] was used to reveal increased isoaspartate 
methylation at liver protein bands of 75-80 kDa, 
95-100 kDa, and 155-160 kDa. Column chroma-
tography used to enrich isoaspartate-damaged 
liver proteins indicated that damaged proteins from 
ethanol-fed rats mirrored those that accumulate in 
the livers of PIMT knockout mice. The about 160 
kDa protein target of PIMT was further purified and 
Sumoylation is often increased under oxidative stress[42]. 
Recent reports demonstrate that ubiquitin conjugating 
enzyme 9 (Ubc9), the sole E2 enzyme of sumoylation, 
is induced in ethanol treated mice[43]. However, the 
functional significance of this finding remains unknown. 
However, a number of sumoylated proteins have been 
identified in the liver after ethanol administration and 
other injury models. A notable example is the enzyme 
methionine adenosyltransferase Ⅱ α (MATα2) which 
has been shown to increase upon ethanol exposure[44] is 
sumoylated. This modification likely plays a critical role 
in its stability[45]. 
Nrf2, a well-characterized transcription factor is 
known for its role in activating anti-oxidant response 
element (ARE), forms heterodimers with small Maf 
(MafG, MafK and MafF) proteins. We recently reported 
that Nrf2 and MafG are sumoylated and this facilitates 
their heterodimerization and trans-activation of the 
ARE in activated hepatic stellate cells[46]. 
Increased levels of lipopolysaccharide (LPS), a 
major component of the cell wall of gram-negative 
bacteria, is frequently found in cirrhotic patients[47] 
and is observed to lower glutathione (GSH), a potent 
anti-oxidant. GSH is highly concentrated in the liver 
and synthesized in the cytosol in a tightly regulated 
manner. Key determinants of GSH synthesis are the 
availability of the sulfur amino acid precursor, cysteine, 
and the activity of the rate-limiting enzyme, glutamate 
cysteine ligase, which is composed of a catalytic and a 
modifier (GCLM) subunit. LPS inhibits the sumoylation 
machinery suppressing the expression of the sole E2 
enzyme Ubc9. This results in reduced Nrf2 and MafG 
sumoylation affecting their heterodimerization and 
trans-activation of the ARE present in GCLC and GCLM 
in macrophages and hepatocytes[48]. 
Although considerable progress has been made 
in the identification of sumoylated proteins and the 
characterization of the effects of the modification of 
these particular substrates, little is known in regards to 
the global regulation of SUMO conjugation in ALD.
ISOASPARTYL DAMAGE
Ethanol consumption specifically triggers a unique 
protein post-translational damage as isoaspartate 
peptide linkages in proteins[49]. This protein isoaspar-
tate damage is due to an inhibition of the protein 
repair enzyme, protein isoaspartyl methyltransferase 
(PIMT). 
PIMT normally acts to resist the accumulation of 
isoaspartate damage that arises through protein 
aging, and as a consequence of oxidative damage 
to proteins[50]. PIMT is a methyltransferase that 
utilises S-adenosylmethionine (SAM) as a methyl 
donor. PIMT methylates isoaspartate residues in 
peptides and proteins, a process that triggers 
isoaspartate elimination and restoration of protein 
function. One of the detrimental actions of ethanol 
consumption is impaired methionine synthase-
6195 July 21, 2016|Volume 22|Issue 27|WJG|www.wjgnet.com
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fractionated, and identified as carbamoyl phosphate 
synthase-1 (CPS-1)[58]. This is a mitochondrial enzyme 
that catalyses the synthesis of carbamoyl phosphate 
from ammonia and bicarbonate, and is the first and 
rate-limiting step of the urea cycle. Resolution of 
liver proteins by one dimensional polyacrylamide gel 
electrophoresis and Coomassie blue staining also 
showed that cytosolic CPS-1 protein levels increased 
by approximately 20% in rats administered ethanol for 
4 wk. A subsequent study of ethanol administration 
for 8 wk showed that the levels of cytosolic CPS-1 
now increased approximately 2-fold over those of 
control animals; indicating that cytosolic CPS-1 levels 
correlated with the duration of alcohol consumption. 
Increased cytosolic CPS-1 was also detected in PIMT 
knockout mice compared to their control littermates. 
This release of liver CPS-1 into the cytosol as a 
response to ethanol consumption or in PIMT knockout 
mice is presumed to reflect mitochondrial damage and 
redox stress. 
These studies highlight the accumulation of 
atypical isoaspartate-containing abnormal proteins 
following chronic ethanol exposure. The animal studies 
employed, however, are of relatively acute alcohol 
administration, and it is hypothesised that in alcoholic 
patients sustained and cumulative isoaspartate protein 
damage across a broad number of target proteins 
would ensue and contribute to liver cell damage and 
pathology. 
METHYLATION
Here, we will discuss the role of this post-translational 
modification in the regulation of innate immunity in 
hepatitis C virus (HCV) infection combined with ethanol 
exposure. About 3% of world population is infected 
with HCV, the most common blood-borne infection 
in the United States. By 2010, 2.7-3.9 million people 
were diagnosed with chronic HCV-infection, and there 
are about 17000 new cases of acute infection per 
year. Hepatitis C and alcohol are the most widespread 
causes of liver disease worldwide, and approximately 
80% of patients with a history of Hepatitis C and 
alcohol abuse develop chronic liver injury[59]. Almost 
one-third of alcoholics with clinical symptoms of liver 
disease have been infected with HCV, which is four 
times the rate of HCV infection found in alcoholics who 
do not have liver disease. Alcohol consumption in HCV-
infected patients exacerbates liver disease leading 
to rapid progression to fibrosis, cirrhosis and even 
hepatocellular carcinoma[60]. Alcohol-consumption 
reduces responsiveness of HCV patients to anti-viral 
treatment; only 7% of heavy drinking HCV patients 
are responders to interferon therapy[61]. However, 
despite the direct acting anti-viral agents (DAA) 
changing the treatment backbone of HCV infection 
from IFN-ribavirin, the effectiveness of DAA would also 
depend on the endogenous IFNα-mediated activation 
of antiviral genes in HCV-infected hepatocytes.
The mechanism by which alcohol consumption 
exacerbates the course of HCV progression is not 
clear. Since HCV and alcohol alter innate immunity 
in hepatocytes, there is a strong possibility that their 
synergistic effect on innate immunity contributes to 
HCV spread and progressive liver injury. Activation of 
an anti-viral innate immune response is based on IFN 
signaling, which requires activation of IFN-sensitive 
genes (ISG) via the Janus kinase/signal transducers 
and activators of transcription (JAK-STAT) pathway. 
Transduction of IFNα signal requires phosphorylation 
of STAT1 and STAT2. The attachment of STAT1 to 
DNA becomes possible if STAT1 is methylated on 
arginine residue(s). It has been shown that HCV 
subverts the IFNα-mediated JAK-STAT signaling 
through the reduction of intrahepatic STAT-1 and -2 
phosphorylation[62] and reduces STAT-1 methylation 
leading to suppression of ISGs[63,64]. 
Ethanol also is known to suppress methylation 
reactions leading to impaired methylation of multiple 
proteins and enzymes[49,51-54]. We hypothesize that 
ethanol potentiates HCV-mediated impairment of 
methylation-regulated IFN signaling in liver cells, 
thereby decreasing antiviral protection in liver cells. 
When HCV-infected Huh7.5-CYP2E1 cells were 
exposed to an extracellular system that continuously 
generates the ethanol metabolite, acetaldehyde (Ach) 
in physiological quantities, STAT1 methylation was 
suppressed on both arginine and lysine residues[65]. 
Suppression of STAT1 methylation is regulated by 
protein arginine N-methyltransferase 1 and lysine 
methyltransferases, and can be induced by specific 
methyltransferase inhibitors. The effects of Ach 
on STAT1 methylation are protein phosphatase 2 
dependent. The impaired methylation of STAT1 
increases the complex formation between STAT1 and 
the pathway inhibitor, protein inhibitor of activated 
STAT-1 (PIAS1), preventing the attachment of IFN-
activated STAT1 to DNA followed by antiviral gene 
activation. This mechanism is schematically presented 
as Figure 1. Methylation-dependent dysregulations 
of IFN signaling in hepatocytes were attenuated by 
supplementation with the pro-methylating agent, 
betaine[65]. 
Thus, Ach potentiates the ability of HCV to down-
regulate activation of ISGs by interferon and plays a 
pivotal role in methylation-dependent suppression of 
innate immunity in hepatocytes, which are primary 
sites of both HCV replication and ethanol metabolism. 
OXIDIZED METABOLITES OF FATTY 
ACIDS
Alcohol administration results in increased production 
of enzymatic or non-enzymatic lipid oxidation products, 
which may also cause protein modifications and 
potential functional damage to proteins[11] as well as 
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impact on the function of various metabolic pathways 
exacerbating alcohol-induced hepatic injury. Many lines 
of evidence, from animals to humans, have shown that 
dietary factors, including dietary fat, along with heavy 
alcohol consumption, play critical roles in the ALD 
pathogenesis. Indeed, the relative beneficial effects 
of dietary saturated fat (SF) and damaging effects of 
dietary unsaturated fat [USF, primarily corn oil/linoleic 
acid (LA) enriched] on alcohol-induced liver injury have 
been well documented in experimental animal models 
of ALD[66-72]. A number of mechanisms have been 
proposed for the opposing effects of dietary USF vs SF 
in ALD, including (1) induction of lipid peroxidation and 
oxidative stress[70,73,74]; (2) altered gut microbiota, 
impaired intestinal barrier integrity, endotoxemia, 
and associated increase in liver pro-inflammatory 
cytokine production[66,67,72]; (3) modulation of hepatic 
lipid metabolism via SIRT1-SREBP-1-histone H3 
axis[75]; and (4) modulation of hepatocyte nuclear 
factor-4α expression, a master transcription factor in 
the regulation of lipid metabolism[76]. A new concept 
has recently emerged that the bioactive oxidized LA 
metabolites (OXLAMs), which are formed enzymatically 
from LA primarily via the actions of 12/15-lipoxygenase 
(12/15-LOX), or non-enzymatically via free radical-
mediated oxidation in response to oxidative stress, 
might contribute to ALD pathogenesis. It has been 
demonstrated that plasma OXLAMs, specifically 
9- and 13-hydroxy-octadecadienoic acids (9- and 
13-HODEs), were elevated in patients with alcoholic 
cirrhosis in parallel with the increase in lipoxygenases 
(15-LOX-1 and 15-LOX-2 mRNA) in the liver samples. 
The plasma levels of HODEs in patients with ALD 
were significantly higher than in healthy subjects as 
well as in NAFLD patients[77]. Further, increased levels 
of 9- and 13-HODEs were observed in experimental 
animal models of ALD[78,79] in parallel with the hepatic 
steatosis, oxidative stress, and inflammation and 
hepatocyte damage. It has been reported that 9- and 
13-HODEs are natural endogenous ligands for the 
Transient Receptor Potential Vanilloid 1 (TRPV1)[80,81]. 
Our recent study demonstrated that chronic-binge 
ethanol-mediated increases in circulating OXLAMs 
and TRPV1 levels in mice were associated with 
hepatic steatosis, inflammation and injury[78]. Genetic 
depletion of TRPV1 did not blunt hepatic steatosis 
caused by ethanol, but prevented hepatic injury. 
TRPV1 deficiency protected from hepatocyte death 
and prevented the increase in pro-inflammatory 
cytokine and chemokine expression, including TNF-α, 
interleukin-6, macrophage inflammatory protein-2 and 
monocyte chemotactic protein-1. Moreover, TRPV1 
depletion markedly blunted ethanol-mediated induction 
of plasminogen activator inhibitor-1, an important 
mediator of alcohol-induced hepatic inflammation, 
via fibrin accumulation[78]. Exposure of HepG2 cells 
to 9- and 13-HODEs resulted in activation of TRPV1 
signal transduction with the increased intracellular Ca2+ 
levels, suggesting that OXLAM/TRPV1/Ca2+ signaling 
may be a relevant pathway contributing to ALD 
pathogenesis.
Alcohol consumption increases hepatic oxida-
tive stress with the production of reactive oxygen 
species. One of the major sources of in vivo protein 
modification during oxidative stress is thought to 
be oxidative products of polyunsaturated fatty acids 
(PUFAs). LA is the most abundant PUFA in mammalian 
tissue. Non-enzymatic oxidative degradation of PUFAs, 
including LA, generate a variety of lipid peroxidation 
products (LPOs, e.g., MDA, HNE, acrolein, various 
epoxyketooctadecenoic acid isomers)[11]. Enhanced 
amounts of peroxidized phospholipids and their 
truncation products in the circulation have previously 
been observed in rats with alcohol-induced liver 
disease[79]. Some LPOs can modify DNA, peptides 
and proteins leading to formation of advanced 
lipoxidation end-products (ALEs). These modifications 
can potentially cause functional damage to proteins. 
Numerous LPOs and ALEs exert diverse biologic 
activities (e.g., damaging and pro-inflammatory effects 
in some cases) through different as yet not well-
defined mechanisms. The role and the significance of 
oxidized lipids, both dietary and in vivo-produced, as 
well as possible mechanisms underlying their beneficial 
or deleterious effects in liver pathology remain to be 
determined.
CONCLUSION
In summary, chronic ethanol consumption dysregulates 
post-translational modifications of numerous important 
proteins that regulate many cellular processes. Not 
surprisingly, there is considerable overlap in the 
pathways that are targeted. Understanding how 
each individual modification affects specific protein 
function and thereby, alters metabolic pathways will 
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Figure 1  Acetaldehyde suppresses interferon-α signaling in hepatitis C 
virus -infected liver cells by impairing signal transducers and activators 
of transcription 1 methylation. The most downstream event in interferon 
(IFN)α signaling is the attachment of methylated STAT1 to DNA, interferon 
stimulated response element (ISRE) and gamma-interferon activated site (GAS), 
for activation of anti-viral interferon-stimulated genes (ISGs). Acetaldehyde 
suppresses STAT1 methylation, which facilitates increased STAT1 interaction 
with protein inhibitor of activated STAT 1 (PIAS1, a negative regulator of IFN 
signaling) preventing STAT1 binding to DNA. This ultimately results in reduced 
ISG activation and decreased induction of anti-viral proteins.
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be of critical importance to deciphering the impact of 
the aforementioned modifications to alcohol- induced 
steatosis and hepatocellular damage. It could also 
provide an insight into disease pathogenesis and 
progression, and may help to identify additional useful 
targets of drug action. In addition, the activation 
of enzymatic and/or non-enzymatic degradation of 
polyunsaturated fatty acids resulting in the formation 
of numerous bioactive lipid compounds underlies 
the deleterious effects of certain dietary fat intake in 
promoting indices of alcoholic liver damage. 
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